Analyst Rating Update on Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) : The consensus on Agios Pharmaceuticals (NASDAQ:AGIO) based on 6 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Agios Pharmaceuticals (NASDAQ:AGIO) : 5 Wall Street analysts covering Agios Pharmaceuticals (NASDAQ:AGIO) believe that the average level the stock could reach for the short term is $64.6. The maximum price target given is $90 and the minimum target for short term is around $47, hence the standard deviation is calculated at $16.18.

For the current week, the company shares have a recommendation consensus of Buy.

Agios Pharmaceuticals (NASDAQ:AGIO): stock turned positive on Tuesday. Though the stock opened at $41.3, the bulls momentum made the stock top out at $44.11 level for the day. The stock recorded a low of $41.3 and closed the trading day at $43.885, in the green by 8.98%. The total traded volume for the day was 786,974. The stock had closed at $40.27 in the previous days trading.

In an insider trading activity, Biller Scott, officer (Chief Scientific Officer) of Agios Pharmaceuticals Inc, unloaded 27,500 shares at an average price of $65 on June 8, 2016. The total amount of the transaction was worth $1,787,500, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Agios Pharmaceuticals, Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221, AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.